Polypharmacological Targeting of G2019S Mutant LRRK2 and JNK3 for the Discovery of a Lead Compound against Parkinson’s Disease
- 22 June 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 16061-16081
Abstract
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder for which single-target therapeutic strategies have shown limited success. To address this challenge, we pursued a structure-based polypharmacological approach targeting both the hyperactive G2019S mutant of leucine-rich repeat kinase 2 (LRRK2G2019S) and c-Jun N-terminal kinase 3 (JNK3), two kinases implicated in PD pathogenesis. Virtual screening, de novo design, and biological evaluation identified N2-phenyl-9H-purine-2,6-diamine (NPPD)-based scaffolds as promising dual-target hits. Subsequent macrocyclization and systematic structure-activity relationship optimization led to inhibitors with improved potency and drug-like properties. Among these, compound 17 exhibited low-nanomolar enzymatic inhibition against both kinases and exceptional picomolar cellular potency against LRRK2G2019S. While optimal cellular activity against JNK3 remains challenging, compound 17 demonstrated a favorable kinome-wide selectivity profile. Pharmacokinetic studies revealed excellent oral exposure, moderate clearance, and efficient brain penetration without observable toxicity. Overall, this study identifies a promising lead compound with significant potential as a therapeutic agent for PD.Keywords
Funding Information
- National Research Foundation of Korea (RS-2025-00563429)
- Institute for Basic Science (IBS-R010-A2)
This publication has 56 references indexed in Scilit:
- LRRK2 Mediates α-Synuclein-Induced Neuroinflammation and Ferroptosis through the p62-Keap1-Nrf2 Pathway in Parkinson’s DiseaseInflammation, 2025
- Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's DiseasesAngewandte Chemie International Edition, 2024
- The molecular mechanism of ferroptosis and its relationship with Parkinson's diseaseBrain Research Bulletin, 2024
- Structural analysis of the full-length human LRRK2Cell, 2021
- Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in NeurodegenerationDrugs in R&D, 2019
- Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target EngagementCell Chemical Biology, 2018
- Measuring and interpreting the selectivity of protein kinase inhibitorsJournal of Chemical Biology, 2009
- Critical assessment of the automated AutoDock as a new docking tool for virtual screeningProteins: Structure, Function, and Bioinformatics, 2006
- Features of Selective Kinase InhibitorsChemistry & Biology, 2005
- Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy functionJournal of Computational Chemistry, 1998